Features and research progressions in triple negative breast cancer

doi:10.3969/j.issn.1006-7795.2015.04.012

Abstract

Abstract:

Triple negative breast cancer(TNBC) is defined as one of the subtypes of breast cancer, which has been attracted much attention in recent years because of the aggressive behavior and inferior prognosis. This review summarizes clinical pathologic features, molecular biologic features and treatments of TNBC. Clinical pathologic features include epidemiologic, clinical and pathobiologic features. Molecular biologic features demonstrate the relationship between TNBC and basal-like breast cancer, breast cancer 1(BRCA1) and p53 gene. Treatments include surgery, neoadjuvant chemotherapy, high dose chemotherapy and targeted therapy. Further research in TNBC may provide more effective therapies.

Key words: triple negative breast cancer, feature, treatment, progression

CLC Number:

R339.2

Du Juan, Ruan Xiangyan. Features and research progressions in triple negative breast cancer[J]. Journal of Capital Medical University, 2015, 36(4): 578-582.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2015.04.012

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2015/V36/I4/578

References

[1] Dent R, Trudeau M, Pritchard K I, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007,13(15 Pt 1):4429-4434.
[2] Brewster A M, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry[J]. Lancet Oncol, 2014,15(13):e625-e634.
[3] 袁中玉,王树森,朱美琴,等.不同分子亚型乳腺癌的临床特征和预后[J].中华肿瘤杂志,2008,30(6):456-461.
[4] Millikan R C, Newman B, Tse C K, et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat, 2008,109(1):123-139.
[5] Yuan Z Y, Wang S S, Gao Y, et al. Clinical characteristics and prognosisof triple-negative breast cancer: a report of 305 cases[J]. Ai Zheng, 2008,27(6):561-565.
[6] 洪雷,魏素菊,马静,等.501例三阴乳腺癌患者预后生存因素分析[J].中国卫生统计,2015,32(1):66-67.
[7] Hernandez-Aya L F, Chavez-MacGregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer[J]. J Clin Oncol, 2011,29(19):2628-2634.
[8] Rakha E A, EI-Sayed M E, Green A R, et al. Prognostic marker in triple-negative breast cancer[J]. Cancer, 2007,109(1):25-32.
[9] Mrklic I, Pogoreli Z, Capkun V, et al. Expression of androgen receptors in triple negative breast carcinomas[J]. Acta Histochem, 2013,115(4):344-348.
[10] Heitz F, Harter P, Lueck H J, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases[J]. Eur J Cancer, 2009,45(16):2792-2798.
[11] Zhang L, Hao C, Dong G, et al. Analysis of Clinical Features and Outcom of 356 Triple-Negative Breast Cancer Patients in China[J]. Breast Care(Basel), 2012,7(1):13-17.
[12] 张丽,赵晓辉,佟仲生,等.356例三阴性乳腺癌的临床特征及预后多因素分析[J].中国肿瘤临床,2010,37(18):1045-1049.
[13] 张毅,王燕,李玉军,等.三阴性乳腺癌的临床病理学特点及其预后影响因素[J/CD].中华普通外科学文献:电子版,2010,4(4):336-340.
[14] 王宝娜,王翔,王靖,等.三阴性乳腺癌578例临床病理特点及预后分析[J/CD].中华临床医师杂志:电子版,2012,6(1):26-29.
[15] Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000,406(6797):747-752.
[16] Banerjee S, Reis-Filho J S, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy[J]. J Clin Pathol, 2006,59(7):729-735.
[17] Nielsen T O, Hsu F D, Jensen K, et al. Immunohistochenical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004,10(16):5367-5374.
[18] Wang Z C, Lin M, Wei L J, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancer[J]. Cancer Res, 2004,64(1):64-71.
[19] Fasano J, Muggia F. Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development[J]. Ann Oncol, 2009,20(4):609-614.
[20] Foulkes W D, Stefansson I M, Chappuis P O, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer[J]. J Natl Cancer Inst, 2003,95(19):1482-1485.
[21] 陈曲,哈敏文,包翠芬.BRCA-1在三阴性乳腺癌中的表达及意义[J].数理医药学杂志,2012,25(5):513-515.
[22] Lakhani S R, Reis-Filho J S, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype[J]. Clin Cancer Res, 2005,11(14):5175-5180.
[23] Livacy C A, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J]. Mod Pathol, 2006,19(2):264-271.
[24] Thompson A M, Lane D P. P53 transcriptional pathways in breast cancer: the good, the bad and the complex[J]. J Pathol, 2010,220(4):401-403.
[25] Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J]. Breast Cancer Res, 2006,8(4):R34.
[26] 何奇,王杰,邵玉国,等.三阴性乳腺癌的临床病理特征与预后分析[J].中华医学杂志,2009,89(4):243-247.
[27] 张勤,刘红.p53 在三阴性乳腺癌中的表达及临床意义[J].中国肿瘤临床,2011,38(4):214-217.
[28] Linderholm B K, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor(VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer[J]. Ann Onc, 2009,20(10):1639-1646.
[29] Riaz M, van Jaarsveld M T, Hollestelle A, et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific mirnas[J]. Breast Cancer Res, 2013,15(2):R33.
[30] Cascione L, Gasparini P, Lovat F, et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer[J]. PLoS One, 2013,8(2):e55910.
[31] Hu J, Xu J, Wu Y, et al. Identification of microRNA-93 as functional dysregulated miRNA in triple-negative breast cancer[J]. Tumour Biol, 2015,36(1):251-258.
[32] Black D M, Hunt K K, Mittendorf E A. Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801[J]. Gland Surg, 2013,2(3):120-123.
[33] Steward L T, Gao F, Taylor M A, et al. Impact of radiation therapy on survival in patients with triple-negative breast cancer[J]. Oncol Lett, 2014,7(2):548-552.
[34] Caudle A S, Yu T K, Tucker S L, et al. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy[J]. Breast Cancer Res, 2012,14(3):R83.
[35] 周波,谢菲,王思源,等.紫杉类联合蒽环类的新辅助化疗方案治疗三阴乳腺癌的疗效及预后[J].中国癌症杂志,2009,19(2):129-132.
[36] Sikov W M, Berry D A, Perou C M, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603(Alliance)[J]. J Clin Oncol, 2015,33(1):13-21.
[37] Gluz O, Nitz U A, Harbeck N, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial[J]. Ann Oncol, 2008,19(5):861-870.
[38] Golshan M, Garber J E, Gelman R, et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?[J]. Ann Surg Oncol, 2011,18(3):733-737.